---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-269869"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:39:55.657386+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Werewolf announces preliminary Phase 1/1b data for WTX-124 showing proof of mechanism and early antitumor activity

## Summary
- 16 heavily pretreated patients in first four monotherapy dose cohorts (1-12 mg); no dose-limiting toxicities or VLS observed.
- Two unconfirmed partial responses at 12 mg; one additional patient with evidence of antitumor activity.
- CD8+ T and NK cell proliferation/activation in tumor microenvironment seen at 6 mg and 12 mg.
- Dose escalation ongoing; cohort 5 (18 mg) fully enrolled; RDE and expansion arms expected H1 2024.
- WTX-124 generally well-tolerated in outpatient setting with all TEAEs Grade 1-2.

## SEC filing metadata
- accession: 0001193125-23-269869
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312523269869/0001193125-23-269869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312523269869/d503964d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-269869
- JSON: https://secwatch.observer/filing/0001193125-23-269869.json
- Plain text: https://secwatch.observer/filing/0001193125-23-269869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.